Accelerating Innovation at Leica Biosystems

Life Sciences Platform Evolution 2015 $3.3B Revenue By End-Market Revenue By 2021E ~$14.5B End-Market Clinical LSD CORE REV. GROWTH Clinical Biopharma >20% CORE REV. GROWTH Rsrch./ Acad. Ind. ~45% RECURRING REV. Research Applied >70% RECURRING REV. Biopharma Applied <15% OPERATING MARGIN Ind. >25% OPERATING MARGIN Pharma Leica MICROSYSTEMS Pre-2009 MOLECULAR DEVICES SCIEX 2010 BECKMAN COULTER Life Sciences Xitogen A PALL 2013 2015 idbs IDT cytiva aldevron INTEGRATED DNA TECHNOLOGIES 2017 2019 Today Enhancing our position with DBS rigor & strategic M&A DANAHER

View entire presentation